Ernexa Therapeutics (ERNAW) Change in Receivables (2010 - 2025)
Ernexa Therapeutics (ERNAW) reported Change in Receivables of -$58000.0 for Q4 2025, down 123.2% on a YoY basis from $250000.0 in Q4 2024, and down 5700.0% quarter-over-quarter from -$1000.0 in Q3 2025.
Ernexa Therapeutics (ERNAW) Change in Receivables (2010 - 2025) Analysis & Trends
Ernexa Therapeutics has reported Change in Receivables for 15 years, with the latest figure at -$58000.0 in Q4 2025.
- For the quarter ending Q4 2025, Change in Receivables fell 123.2% year-over-year to -$58000.0; the trailing twelve-month figure through Dec 2025 stood at -$342000.0 (down 2950.0% YoY), and the FY2025 full-year result was -$342000.0, down 2950.0% from the prior year.
- Change in Receivables for Q4 2025 stood at -$58000.0, down from -$1000.0 in the prior quarter.
- The five-year high for Change in Receivables was $792000.0 in Q3 2023, with the low at -$1.4 million in Q4 2023.
- Historically, Change in Receivables has averaged $3368.4 across 5 years, with a median of -$2000.0 in 2025.
- The largest YoY upside for Change in Receivables was 3750.0% in 2022 against a maximum downside of 14000.0% in 2022.
- Ernexa Therapeutics' Change in Receivables stood at $664000.0 in 2021, then tumbled by 96.23% to $25000.0 in 2022, then slumped by 5508.0% to -$1.4 million in 2023, then soared by 118.49% to $250000.0 in 2024, then plunged by 123.2% to -$58000.0 in 2025.
- The last three Change in Receivables figures came in at -$58000.0 (Q4 2025), -$1000.0 (Q3 2025), and -$2000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Ernexa Therapeutics | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -58,000.00 |
| Dec 31, 2025 | -58,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -2,000.00 |
| Jun 30, 2025 | -2,000.00 |
| Mar 31, 2025 | -281,000.00 |
| Mar 31, 2025 | -281,000.00 |
| Dec 31, 2024 | 250,000.00 |
| Dec 31, 2024 | 250,000.00 |
| Sep 30, 2024 | -41,000.00 |
| Sep 30, 2024 | -41,000.00 |
| Jun 30, 2024 | -123,000.00 |
| Jun 30, 2024 | -123,000.00 |
| Mar 31, 2024 | -74,000.00 |
| Mar 31, 2024 | -74,000.00 |
| Dec 31, 2023 | -1.35 Mn |
| Dec 31, 2023 | -1.35 Mn |
| Sep 30, 2023 | 792,000.00 |
| Sep 30, 2023 | 792,000.00 |